Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY AI Verdict: PROCEED
Price: $901.12 Analyst target: $1147.35 Upside: 27.32%
argenx is a high-quality immunology franchise (Vyvgart) with Q3 sales of $1.72B (+54%), EPS growth ~51% and a 31.7% profit margin. The price is above a rising SMA200 (594) and SMA50 (854), ADX is 34.9 (trending), and the pullback to a stochastic K of 18 with a weekly bounce to 873 is a reasonable entry. The likely catalyst is the strong Q3 beat, the seronegative MG halo effect, five planned 2027 U.S. launches and an Oddo BHF target raise, with news sentiment Somewhat-Bullish (22 bullish vs 7 bearish).
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
See the full interactive analysis & chart →Informational only — not investment advice.